FDA-approved testing that identifies homologous recombination deficiency (HRD) status.
Consented intake · your records travel with you · nothing moves without your sign-off
Myriad Genetics offers myChoice CDx, an FDA-approved companion diagnostic that identifies homologous recombination deficiency (HRD) status. It is for patients whose treatment decisions may depend on whether their tumor carries HRD. As a companion diagnostic, the test is designed to pair with treatment decisions, giving patients and their doctors a defined result to factor into the plan.
Prefer the source? Myriad Genetics's own site has more.
The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how Myriad Genetics handles billing.
Accepted
Available
Required
In-network carriers
Myriad accepts insurance; In-network carriers include Medicare, Blue Cross Blue Shield, UnitedHealthcare, Aetna; financial assistance is available. Add your plan on OpenCancer to check coverage before you commit.
Through OpenCancer's consented intake: enter your details once, choose exactly which records travel with the request, and sign a consent that covers this connection only. Nothing is shared without your sign-off.
Answers grounded in Myriad's details here. Educational only; your oncologist directs treatment.
Powered by Navis on opencancer.ai
Cancer types served
Other providers in similar categories.
FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.
Tempus xT is a comprehensive genomic profiling test combining DNA and RNA sequencing to identify actionable mutations.
Invitae offers genetic testing for hereditary cancer syndromes including BRCA1/2, Lynch syndrome, and other inherited cancer risks.
Guardant360 is a comprehensive liquid biopsy test that analyzes ctDNA to identify genomic alterations and guide treatment decisions.
This page is general information. Upload your records for analysis specific to YOUR diagnosis.